TABLE 3.
Study location, neutralization result, and virus | Clade | IC50 (μg/ml) |
---|---|---|
UMass | ||
Positive neutralization | ||
MN | B | 27.5 |
SF162 | B | 3.67 |
SS1196 | B | 2.23 |
QH0692.42 | B | 31.8 |
Negative neutralization | ||
NL4-3 | B | >50 |
SC422661 | B | >50 |
WITO4160 | B | >100 |
ZM109F.PB4 | C | >50 |
Du156 | C | >50 |
Du422.1 | C | >100 |
ZM197.pB7 | C | >50 |
CM235.c11 | CRF01_AE | >50 |
816367.CO2 | CRF01_AE | >50 |
MLV | >50 | |
Harvard | ||
Positive neutralization | ||
SS1196.1 | B | 30.08 |
T271-11 | CRF02_AG | 59.08 |
Negative neutralization | ||
MS208.A1 | A | >100 |
Q23.17 | A | >100 |
MN-3 | B | >100 |
SF162.LS | B | >100 |
BaL.26 | B | >100 |
6535.3 | B | >100 |
MW965.26 | C | >100 |
TV1.21 | C | >100 |
ZM109F.PB4 | C | >100 |
DJ263.8 | CRF02_AG | >100 |
242-14 | CRF02_AG | >100 |
TH023.6 | CRF01_AE | >100 |
IC50, 50% inhibitory concentration; UMass, University of Massachusetts Medical School; Harvard, Harvard Medical School; MLV, murine leukemia virus.